rs1040524947
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP6
The NM_002691.4(POLD1):c.589A>C(p.Ser197Arg) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.00000373 in 1,609,898 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000021 ( 0 hom. )
Consequence
POLD1
NM_002691.4 missense, splice_region
NM_002691.4 missense, splice_region
Scores
3
10
6
Splicing: ADA: 0.2665
2
Clinical Significance
Conservation
PhyloP100: 4.29
Genes affected
POLD1 (HGNC:9175): (DNA polymerase delta 1, catalytic subunit) This gene encodes the 125-kDa catalytic subunit of DNA polymerase delta. DNA polymerase delta possesses both polymerase and 3' to 5' exonuclease activity and plays a critical role in DNA replication and repair. Alternatively spliced transcript variants have been observed for this gene, and a pseudogene of this gene is located on the long arm of chromosome 6. [provided by RefSeq, Mar 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -1 ACMG points.
BP6
Variant 19-50402124-A-C is Benign according to our data. Variant chr19-50402124-A-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 537130.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLD1 | NM_002691.4 | c.589A>C | p.Ser197Arg | missense_variant, splice_region_variant | 5/27 | ENST00000440232.7 | NP_002682.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLD1 | ENST00000440232.7 | c.589A>C | p.Ser197Arg | missense_variant, splice_region_variant | 5/27 | 1 | NM_002691.4 | ENSP00000406046 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152106Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152106
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000206 AC: 3AN: 1457792Hom.: 0 Cov.: 34 AF XY: 0.00000138 AC XY: 1AN XY: 724890
GnomAD4 exome
AF:
AC:
3
AN:
1457792
Hom.:
Cov.:
34
AF XY:
AC XY:
1
AN XY:
724890
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152106Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74296
GnomAD4 genome
AF:
AC:
3
AN:
152106
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74296
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 22, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in co-occurrence with a damaging CHEK2 variant in an individual with colon polyps who had a family history of breast and other cancers; however, the damaging CHEK2 variant was also identified in an individual in this family with early-onset breast cancer (PMID: 30374176); This variant is associated with the following publications: (PMID: 30374176) - |
Colorectal cancer, susceptibility to, 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces serine, which is neutral and polar, with arginine, which is basic and polar, at codon 197 of the POLD1 protein (p.Ser197Arg). This variant is present in population databases (no rsID available, gnomAD 0.007%). This missense change has been observed in individual(s) with colon polyps and breast cancer (PMID: 30374176). ClinVar contains an entry for this variant (Variation ID: 537130). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Familial colorectal cancer Benign:1
Likely benign, criteria provided, single submitter | research | University of Washington Department of Laboratory Medicine, University of Washington | May 09, 2018 | The POLD1 variant designated as NM_002878.3:c.394G>A (p.Val132Ile) is classified as likely benign. In one observed family, a family with the variant had colon polyps that did not show the molecular ultramutation phenotype that is the signature of pathogenic POLD1 mutations (Briggs et al, 2013, PMID: 23447401). This variant is not in the POLD1 exonuclease domain and is unlikely to cause increased cancer risk, as only POLD1 variants that alter exonuclease activity have been documented to be associated with colon and endometrial cancer risk. Additionally, in the same family, in the POLD1 variant often co-occurs with a likely-pathogenic mutation in the CHEK2 gene (p.R145W). Bayesian analysis integrating all of this data (Tavtigian et al, 2018, PMID:29300386) gives about 1% probability of pathogenicity, which is consistent with a classification of likely benign. This variant is not predicted to alter POLD1 function or modify cancer risk. A modest (less than 2 fold) increase in cancer risk due to this variant cannot be entirely excluded. This analysis was performed in conjunction with the family studies project as part of the University of Washington Find My Variant Study. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
T;.;.;.;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
.;.;T;T;T
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Pathogenic
M;.;.;.;M
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;.;.;.;.
REVEL
Benign
Sift
Uncertain
D;.;.;.;.
Sift4G
Uncertain
D;D;D;D;D
Polyphen
P;.;.;.;P
Vest4
MutPred
Loss of phosphorylation at S197 (P = 0.0561);Loss of phosphorylation at S197 (P = 0.0561);Loss of phosphorylation at S197 (P = 0.0561);Loss of phosphorylation at S197 (P = 0.0561);Loss of phosphorylation at S197 (P = 0.0561);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
dbscSNV1_RF
Benign
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at